Dr.Follen (MS)

1. Which medications have a Boxed Warning for teratogenicity?

• Alemtuzumab (Lemtrada)

• Mitoxantrone (Novantrone)

• Teriflunomide (Aubagio)

• Cladribine (Mavenclad)

1. List two adverse effects of glatiramer acetate (Copaxone)

• Nausea, headache
• Back pain, dizziness
• Injection site reactions, immediate post-injection reactions

• Rash, fever

Answer explanation

INJECTION-SITE REACTIONS:

Indurations, masses, and welts
may last days after injection
• Pain, erythema, urticaria

Immediate POST-INJECTION
REACTIONS:
Flushing, vasodilation, chest
tightness, palpitations,
tachycardia, throat
constriction, dyspnea, anxiety,
urticaria

1. What are the Boxed Warnings for alemtuzumab?

• N&V

• 
  Autoimmune conditions

• 
  Malignancies

• Infusion reactions

1. What is the name of the REMS program associated with Natalizumab?

• Safety program
• Natalizumab program
• TOUCH program
• REMS program

1. Which medication carries a Boxed Warning for PML and has a REMS program for it?

• Teriflunomide (Aubagio)

• 1. Ocrelizumab (Ocrevus)

• 1. Ofatumumab (Kesimpta)

• Tysabri (natalizumab)

1. What is a contraindication that is similar to both ofatumumab (Kesimpta) and ocrelizumab (Ocrevus)?

• Active hepatitis B infection
• Seasonal allergies
• High blood pressure
• Type 1 diabetes

1. Which medication should be avoided/used with caution in patients with depression?

• Interferon Beta

• Monoclonal Antibody
  Infusions

• Fumarates

• Sphingosine 1-Phosphate (S1P)
  Receptor Agonist

Answer explanation

Avonex, Rebif, Plegridy, Betaseron, Extavia

1. Which medications may be considered for use during pregnancy?

• BETASERON

• PLEGRIDY

• REBIF

• AVONEX

• EXTAVIA

1. Should cladribine (Mavenclad) be used as a first-line therapy for MS?  Should it be used for CIS?

• Yes, considered first line treatment

• Not recommended for CIS

• No, considered second-line treatment due to safety profile.

• Yes recommended for CIS

1. Which medication has a Boxed Warning for hepatotoxicity?

• Teriflunomide (Aubagio)

• 1. Glatiramer acetate (Copaxone)

• Ocrelizumab (Ocrevus)

• Ofatumumab (Kesimpta)